Skip to main content
Premium Trial:

Request an Annual Quote

DermTech Raises $5.6 Million in Series B Round

NEW YORK (GenomeWeb News) – DermTech today announced that it has raised $5.6 million in a private round of financing to support future development and commercialization of its qPCR-based melanoma detection assay.

Jacobs Investment Company led the Series B financing with additional investments coming from other existing and new investors, which were not named.

DermTech will use the funds to complete commercial validation of the melanoma test — its first product — and to establish a CLIA-certified lab facility in order to provide clinical testing services, the company said.

The company's melanoma test measures the expression of multiple gene targets in RNA extracted from skin samples collected using custom adhesive strips that non-invasively lift cells from suspicious lesions.

DermTech began evaluating PCR platforms to support its commercial melanoma assay in 2011, but it has not yet disclosed what platform the test will run on.

According to DermTech, clinical studies have demonstrated that the test has the ability to distinguish melanoma from non-melanoma with greater than 95 percent sensitivity and more than 70 percent specificity.

"The acquisition of the Series B Financing will help the Company tremendously as we continue to validate our assay and drive toward commercialization on this important tool for clinicians," John Dobak, DermTech's president and CEO, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.